As a Free StocksGuide user, you can view scores for all 7,097 stocks worldwide.
7 Analysts have issued a Precipio, Inc. forecast:
7 Analysts have issued a Precipio, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 23 23 |
31%
31%
|
|
| Gross Profit | 10 10 |
47%
47%
|
|
| EBITDA | -0.69 -0.69 |
60%
60%
|
|
| EBIT (Operating Income) EBIT | -2.08 -2.08 |
31%
31%
|
|
| Net Profit | -1.25 -1.25 |
58%
58%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Precipio, Inc. is a cancer diagnostics company, which engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis. Its products include MX-ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HRM kits and ICP liquid biopsy testing. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
| Head office | United States |
| CEO | Ilan Danieli |
| Employees | 57 |
| Founded | 1997 |
| Website | www.precipiodx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


